
Sign up to save your podcasts
Or


In the debut episode of Pricing & Policy with Model N — a new podcast series from Pharmaceutical Executive — Model N VP of product management Michael Grosberg joins host Mike Christel to break down what the company's annual state of revenue survey reveals about the mounting pressures threatening pharma's commercial foundation. From PBM opacity and Medicaid withdrawal to "ghost claims" lurking inside DTC channels, this conversation pulls back the curtain on the industry's most consequential — and perhaps least understood — business challenge: revenue management.
01:50 - Drivers of rising GTN complexity.
05:08 - The Medicaid dilemma: Exiting the program.
08:30 - Coordination of benefits and rebate eligibility: “We’re doing a really poor job at this.”
10:57 - The easiest way to solve the problem.
12:04 - IRA’s Medicare drug price negotiations: Where we stand.
16:20 - Launch strategy and sequencing considerations.
20:13 - MFN agreements transparency.
21:51 - Data disconnect blurs pricing and revenue visibility.
24:05 - AI "catch-up" imperatives for revenue management.
27:48 - System strain? DTC’s downstream impacts.
33:36 - Top threats to future model.
By Pharmaceutical Executive Podcast4.9
1414 ratings
In the debut episode of Pricing & Policy with Model N — a new podcast series from Pharmaceutical Executive — Model N VP of product management Michael Grosberg joins host Mike Christel to break down what the company's annual state of revenue survey reveals about the mounting pressures threatening pharma's commercial foundation. From PBM opacity and Medicaid withdrawal to "ghost claims" lurking inside DTC channels, this conversation pulls back the curtain on the industry's most consequential — and perhaps least understood — business challenge: revenue management.
01:50 - Drivers of rising GTN complexity.
05:08 - The Medicaid dilemma: Exiting the program.
08:30 - Coordination of benefits and rebate eligibility: “We’re doing a really poor job at this.”
10:57 - The easiest way to solve the problem.
12:04 - IRA’s Medicare drug price negotiations: Where we stand.
16:20 - Launch strategy and sequencing considerations.
20:13 - MFN agreements transparency.
21:51 - Data disconnect blurs pricing and revenue visibility.
24:05 - AI "catch-up" imperatives for revenue management.
27:48 - System strain? DTC’s downstream impacts.
33:36 - Top threats to future model.

30,666 Listeners

4,137 Listeners

3,217 Listeners

1,720 Listeners

4,345 Listeners

420 Listeners

1,657 Listeners

145 Listeners

1,425 Listeners

9,532 Listeners

337 Listeners

1,302 Listeners

6,089 Listeners

85 Listeners

142 Listeners